Goldman Sachs Group Inc Beam Therapeutics Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 680,848 shares of BEAM stock, worth $18.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
680,848
Previous 784,563 13.22%
Holding current value
$18.3 Million
Previous $18.4 Million 9.26%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$22.57 - $33.14 $2.34 Million - $3.44 Million
-103,715 Reduced 13.22%
680,848 $16.7 Million
Q2 2024

Aug 13, 2024
BUY
$21.22 - $32.66 $4.93 Million - $7.59 Million
232,351 Added 42.08%
784,563 $18.4 Million
Q1 2024

May 15, 2024
BUY
$23.46 - $45.07 $1.6 Million - $3.07 Million
68,062 Added 14.06%
552,212 $18.2 Million
Q4 2023

Feb 13, 2024
BUY
$17.69 - $30.76 $396,839 - $690,039
22,433 Added 4.86%
484,150 $13.2 Million
Q3 2023

May 14, 2024
SELL
$23.01 - $32.46 $516,183 - $728,175
-22,433 Reduced 4.63%
461,717 $11.1 Million
Q3 2023

Nov 14, 2023
SELL
$23.01 - $32.46 $6.08 Million - $8.58 Million
-264,308 Reduced 36.4%
461,717 $11.1 Million
Q2 2023

May 14, 2024
BUY
$29.32 - $35.99 $1.99 Million - $2.44 Million
67,767 Added 10.29%
726,025 $23.2 Million
Q2 2023

Aug 14, 2023
BUY
$29.32 - $35.99 $1.99 Million - $2.44 Million
67,767 Added 10.29%
726,025 $23.2 Million
Q1 2023

May 14, 2024
SELL
$30.15 - $48.79 $10.9 Million - $17.6 Million
-360,134 Reduced 35.36%
658,258 $20.2 Million
Q1 2023

May 11, 2023
SELL
$30.15 - $48.79 $10.9 Million - $17.6 Million
-360,134 Reduced 35.36%
658,258 $20.2 Million
Q4 2022

May 14, 2024
SELL
$36.73 - $51.6 $1.22 Million - $1.72 Million
-33,284 Reduced 3.16%
1,018,392 $39.8 Million
Q4 2022

Feb 13, 2023
SELL
$36.73 - $51.6 $1.22 Million - $1.72 Million
-33,284 Reduced 3.16%
1,018,392 $39.8 Million
Q3 2022

May 14, 2024
BUY
$39.79 - $70.31 $3.89 Million - $6.87 Million
97,749 Added 10.25%
1,051,676 $50.1 Million
Q3 2022

Nov 10, 2022
BUY
$39.79 - $70.31 $3.89 Million - $6.87 Million
97,749 Added 10.25%
1,051,676 $50.1 Million
Q2 2022

May 14, 2024
BUY
$29.86 - $62.36 $14 Million - $29.3 Million
469,777 Added 97.03%
953,927 $36.9 Million
Q2 2022

Aug 15, 2022
BUY
$29.86 - $62.36 $3.72 Million - $7.78 Million
124,680 Added 15.04%
953,927 $36.9 Million
Q1 2022

May 16, 2022
SELL
$53.73 - $82.16 $7.78 Million - $11.9 Million
-144,771 Reduced 14.86%
829,247 $47.5 Million
Q4 2021

Feb 14, 2022
SELL
$68.02 - $99.06 $4.77 Million - $6.94 Million
-70,064 Reduced 6.71%
974,018 $77.6 Million
Q3 2021

Nov 10, 2021
BUY
$84.37 - $133.6 $88.1 Million - $139 Million
1,044,082 New
1,044,082 $90.8 Million

Others Institutions Holding BEAM

# of Institutions
236
Shares Held
75.2M
Call Options Held
438K
Put Options Held
232K
View Full List

About Beam Therapeutics Inc.

BEAM Quotes by TradingView
  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.89B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email